Multiple System Atrophy (MSA) Market Segmentation by Type (Parkinsonian, and Cerebellar); by Diagnosis (Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Tilt Table Test, and Others) – Global Demand Analysis & Opportunity Outlook 2030
Buy Now Report ID: 3440 | Published Date: Feb 08, 2023
Our in-depth analysis of the global multiple system atrophy (MSA) market includes the following segments:
By Type
By Diagnosis
Growth Drivers
Challenges
On the basis of geographical analysis, the global multiple system atrophy (MSA) market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of the increasing number of cases of multiple system atrophy, especially in Japan, high patient pool and growing government initiatives to improve the infrastructure of healthcare in the region. Moreover, the market in North America is expected to gather the largest share during the forecast period, which can be credited to the rising prevalence of neurological disorders, increasing healthcare spending, well established healthcare infrastructure, and strong presence of prominent market players in the region. According to the Centers for Medicare and Medicaid Services, U.S. health care spending grew 4.6 percent in 2019, reaching $3.8 trillion or $11,582 per person. The health spending accounted for 17.7 percent of the country’s total GDP share.
The global multiple system atrophy (MSA) market is further classified on the basis of region as follows:
March 18, 2020- Biohaven Pharmaceutical’s myeloperoxidase (MPO) inhibitor, verdiperstat, received fast track designation from the United States Food and Drug Administration for treating multiple system atrophy or MSA. The drug is aimed at slowing the progression of the disease.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: The major growth drivers for the market are growing occurrence of multiple system atrophy across the world and increasing research and development activities to develop effective treatment for systemic atrophies.
Ans: The market is anticipated to attain a notable CAGR over the forecast period, i.e., 2022 – 2030.
Ans: Lack of awareness about the disease in lower economic regions is estimated to hamper the market growth.
Ans: Asia Pacific will provide more business opportunities for market growth owing to the increasing number of cases of multiple system atrophy, and high patient pool of the region.
Ans: The major players in the market are Chelsea Therapeutics International, Ltd., Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by type, diagnosis, and by region.
Ans: The MRI segment is anticipated to hold largest market size and is estimated to grow at a robust CAGR over the forecast period and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
